Literature DB >> 1233257

Comparative drug elimination in man-diphenylhydantoin and amobarbital.

J F Brien, T Inaba, W Kalow.   

Abstract

The concentration of 5,5-diphenylhydantoin (DPH) in serum was determined at selected time intervals in seven healthy male volunteers starting 10 h after an oral dose of 400 mg sodium DPH was given. The data were analyzed according to a one-compartment model assuming first-order kinetics. The mean serum half-life was 19.28 h +/- 5.87 (SD). A positive correlation coefficient (r=0.84, p less than 0.05) was found between the serum DPH half-life and the serum amobarbital half-life in the seven subjects. The urinary levels of free plus conjugated 5-(p-hydroxyphenyl)-5-phenyl-hydantoin were determined for 12 h periods over a minimum of two days following the 400 mg oral dose of sodium DPH. Subjects with a short DPH half-life tended to excrete in urine a greater amount of p-HPPH as compared to subjects with a long DPH half-life. In the case of one subject, the urinary excretion of p-HPPH plateaued five days after DPH administration and the apparent elimination half-life determined from the p-HPPH urinary excretion data was 19.16 h as compared to the value of 19.53 h calculated from the DPH serum levels.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233257     DOI: 10.1007/bf00613433

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  A METHOD FOR EVALUATION OF PHYSIOLOGICAL AVAILABILITY OF DIPHENYL HYDANTOIN BY URINARY ANALYSIS.

Authors:  T PANALAKS
Journal:  Clin Chim Acta       Date:  1963-11       Impact factor: 3.786

Review 2.  Factors causing interindividual variations of drug concentrations in blood.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

3.  Determination of low levels of 5,5-diphenylhydantoin in serum by gas-liquid chromatography.

Authors:  J F Brien; T Inaba
Journal:  J Chromatogr       Date:  1974-01-30

4.  Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone.

Authors:  D Kadar; T Inaba; L Endrenyi; G E Johnson; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Pharmacokinetics of single and multiple doses of phenytoin in man.

Authors:  L Lund; G Alvan; A Berlin; B Alexanderson
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

7.  Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.

Authors:  D S Davies; S S Thorgeirsson
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

8.  Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration.

Authors:  A J Glazko; T Chang; J Baukema; W A Dill; J R Goulet; R A Buchanan
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

9.  Kinetic considerations relating to the accrual and elimination of drug metabolites.

Authors:  A J Cummings; B K Martin; G S Park
Journal:  Br J Pharmacol Chemother       Date:  1967-02

10.  The rate of decline of diphenylhydantoin in human plasma.

Authors:  K Arnold; N Gerber
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.903

View more
  5 in total

1.  Disposition of antipyrine and phenytoin correlated with age and liver volume in man.

Authors:  B Bach; J M Hansen; J P Kampmann; S N Rasmussen; L Skovsted
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

2.  Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man.

Authors:  L F Gram; P B Andreasen; K F Overo; J Christiansen
Journal:  Psychopharmacology (Berl)       Date:  1976-10-20       Impact factor: 4.530

3.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

4.  Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man.

Authors:  H H Wan; N Thatcher; P W Mullen; G N Smith; P M Wilkinson
Journal:  Br J Cancer       Date:  1979-04       Impact factor: 7.640

5.  Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing.

Authors:  Barbara A Wetmore; John F Wambaugh; Brittany Allen; Stephen S Ferguson; Mark A Sochaski; R Woodrow Setzer; Keith A Houck; Cory L Strope; Katherine Cantwell; Richard S Judson; Edward LeCluyse; Harvey J Clewell; Russell S Thomas; Melvin E Andersen
Journal:  Toxicol Sci       Date:  2015-08-06       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.